Gemcitabine-Based Chemotherapy for Advanced Soft Tissue Sarcoma: Identifying the Appropriate Dose and Schedule
Kenji Nakano(National Center for Global Health and Medicine), Shunji Takahashi(Japanese Foundation For Cancer Research), X. Wang(Tokyo Medical and Dental University), Yuki Funauchi(Japan Association for Development of Community Medicine), Junichi Tomomatsu(The Cancer Institute Hospital), Keiko Hayakawa(Cancer Institute (WIA)), Naoki Fukuda(The Cancer Institute Hospital), Makiko Ono(The Cancer Institute Hospital), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Akihiro Ohmoto(Japanese Foundation For Cancer Research), Mayu Yunokawa(Japanese Foundation For Cancer Research), Naomi Hayashi(The Cancer Institute Hospital), Tetsuya Urasaki(Japanese Foundation For Cancer Research), Keisuke Ae(The Cancer Institute Hospital), Yasuyoshi Sato(The Cancer Institute Hospital)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264